Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feedernews.google.com
enzalutamide - Google News
Get the latest updates from enzalutamide - Google News directly as they happen.
Follow now < 10 followers
Latest posts
Last updated about 8 hours ago
Coactivator Networks Orchestrating Noncanonical AR Programs in Enzalutamide-Resistant CRPC - Frontiers
11 days ago
Coactivator Networks Orchestrating Noncanonical AR Programs in Enzalutamide-Resistant CRPC Frontiers
Monte Rosa shares gain on encouraging prostate cancer trial update - MSN
11 days ago
Monte Rosa shares gain on encouraging prostate cancer trial update MSN
Venetoclax-Enzalutamide Combination Shows Promising Safety and Preliminary Efficacy in mCRPC - OncLive
11 days ago
Venetoclax-Enzalutamide Combination Shows Promising Safety and Preliminary Efficacy in mCRPC OncLive
Monte Rosa stock rises after promising clinical data in prostate cancer By Investing.com - Investing.com Nigeria
11 days ago
Monte Rosa stock rises after promising clinical data in prostate cancer By...
Monte Rosa Therapeutics Announces Positive Interim Data for MRT-2359 in Prostate Cancer - TradingView — Track All Markets
11 days ago
Monte Rosa Therapeutics Announces Positive Interim Data for MRT-2359 in Prostate Cancer...
Monte Rosa Therapeutics Announces Compelling Clinical Activity of MRT-2359 in Combination with Enzalutamide in Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer Patients with Androgen Receptor Mutations - The Manila Times
11 days ago
Monte Rosa Therapeutics Announces Compelling Clinical Activity of MRT-2359 in Combination with...
Monte Rosa Therapeutics announces compelling clinical activity of MRT-2359 in combination with enzalutamide - marketscreener.com
11 days ago
Monte Rosa Therapeutics announces compelling clinical activity of MRT-2359 in combination with...
Monte Rosa Therapeutics Announces Compelling Clinical Activity of MRT-2359 in Combination with Enzalutamide in Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer Patients with Androgen Receptor Mutations - Sahm
11 days ago
Monte Rosa Therapeutics Announces Compelling Clinical Activity of MRT-2359 in Combination with...
Monte Rosa Therapeutics Announces Compelling Clinical - GlobeNewswire
11 days ago
Monte Rosa Therapeutics Announces Compelling Clinical GlobeNewswire
Monte Rosa Therapeutics Announces Compelling Clinical Activity of MRT-2359 in Combination with Enzalutamide in Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer Patients with Androgen Receptor Mutations - Yahoo Finance
11 days ago
Monte Rosa Therapeutics Announces Compelling Clinical Activity of MRT-2359 in Combination with...
Monte Rosa Therapeutics, Inc. Announces Compelling Clinical Activity of MRT-2359 in Combination with Enzalutamide in Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer Patients with Androgen Receptor Mutations - marketscreener.com
11 days ago
Monte Rosa Therapeutics, Inc. Announces Compelling Clinical Activity of MRT-2359 in Combination...
Monte Rosa Therapeutics Announces Compelling Clinical - GlobeNewswire
11 days ago
Monte Rosa Therapeutics Announces Compelling Clinical GlobeNewswire